ALNYLAM PHARMACEUTICALS, INC. Share-based Payment Arrangement, Expense
ALNYLAM PHARMACEUTICALS, INC. (ALNY) reported Share-based Payment Arrangement, Expense of $86.63 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2026-07-30
- ALNYLAM PHARMACEUTICALS, INC. share-based payment arrangement, expense for the quarter ending 2026-06-30 was $86.63M, a 22.43% decline year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. share-based payment arrangement, expense for the quarter ending 2025-12-31 was $71.63M, a 21.84% decline year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. share-based payment arrangement, expense for the quarter ending 2025-09-30 was $108.21M, a 136.25% increase year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. share-based payment arrangement, expense for the quarter ending 2025-06-30 was $111.68M, a 25.08% increase year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. share-based payment arrangement, expense for fiscal 2025 was $348.24M, a 27.99% increase from fiscal 2024.
- ALNYLAM PHARMACEUTICALS, INC. share-based payment arrangement, expense for fiscal 2024 was $272.08M, a 22.74% increase from fiscal 2023.
- ALNYLAM PHARMACEUTICALS, INC. share-based payment arrangement, expense for fiscal 2023 was $221.68M, a 3.89% decline from fiscal 2022.
- ALNYLAM PHARMACEUTICALS, INC. share-based payment arrangement, expense for fiscal 2022 was $230.65M, a 39.18% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Expense 3 month | Share-based Payment Arrangement, Expense 6 month | Share-based Payment Arrangement, Expense 9 month | Share-based Payment Arrangement, Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $86.63M 10-Q · filed 2026-07-30 | $156.78M 10-Q · filed 2026-07-30 | ||
| 2025-12-31 | $71.63M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $179.84M derived: sum of 2 quarters · filed 2026-02-12 | $291.52M derived: sum of 3 quarters · filed 2026-07-30 | $348.24M 10-K · filed 2026-02-12 |
| 2025-09-30 | $108.21M 10-Q · filed 2025-10-30 | $219.89M derived: sum of 2 quarters · filed 2026-07-30 | $276.60M 10-Q · filed 2025-10-30 | $368.25M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | $111.68M 10-Q · filed 2026-07-30 | $168.39M 10-Q · filed 2026-07-30 | $260.04M derived: sum of 3 quarters · filed 2026-07-30 | $305.84M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | $56.71M 10-Q · filed 2025-05-01 | $148.36M derived: sum of 2 quarters · filed 2026-02-12 | $194.16M derived: sum of 3 quarters · filed 2026-02-12 | $283.45M derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-12-31 | $91.64M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $137.45M derived: sum of 2 quarters · filed 2026-02-12 | $226.74M derived: sum of 3 quarters · filed 2026-02-12 | $272.08M 10-K · filed 2026-02-12 |
| 2024-09-30 | $45.80M 10-Q · filed 2025-10-30 | $135.09M derived: sum of 2 quarters · filed 2025-10-30 | $180.44M 10-Q · filed 2025-10-30 | $222.43M derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-06-30 | $89.29M 10-Q · filed 2025-07-31 | $134.63M 10-Q · filed 2025-07-31 | $176.63M derived: sum of 3 quarters · filed 2026-02-12 | $240.57M derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-03-31 | $45.35M 10-Q · filed 2025-05-01 | $87.34M derived: sum of 2 quarters · filed 2026-02-12 | $151.28M derived: sum of 3 quarters · filed 2026-02-12 | $227.08M derived: sum of 4 quarters · filed 2026-02-12 |
| 2023-12-31 | $41.99M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $105.93M derived: sum of 2 quarters · filed 2026-02-12 | $181.73M derived: sum of 3 quarters · filed 2026-02-12 | $221.68M 10-K · filed 2026-02-12 |
| 2023-09-30 | $63.94M 10-Q · filed 2024-10-31 | $139.74M derived: sum of 2 quarters · filed 2024-10-31 | $179.69M 10-Q · filed 2024-10-31 | $222.45M derived: sum of 4 quarters · filed 2025-02-13 |
| 2023-06-30 | $75.80M 10-Q · filed 2024-08-01 | $115.75M 10-Q · filed 2024-08-01 | $158.52M derived: sum of 3 quarters · filed 2025-02-13 | $286.63M derived: sum of 4 quarters · filed 2025-02-13 |
| 2023-03-31 | $39.95M 10-Q · filed 2024-05-02 | $82.71M derived: sum of 2 quarters · filed 2025-02-13 | $210.83M derived: sum of 3 quarters · filed 2025-02-13 | $241.30M derived: sum of 4 quarters · filed 2025-02-13 |
| 2022-12-31 | $42.77M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-13 | $170.88M derived: sum of 2 quarters · filed 2025-02-13 | $201.36M derived: sum of 3 quarters · filed 2025-02-13 | $230.65M 10-K · filed 2025-02-13 |
| 2022-09-30 | $128.12M 10-Q · filed 2023-11-02 | $158.59M derived: sum of 2 quarters · filed 2023-11-02 | $187.88M 10-Q · filed 2023-11-02 | $232.46M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-06-30 | $30.47M 10-Q · filed 2023-08-03 | $59.76M 10-Q · filed 2023-08-03 | $104.35M derived: sum of 3 quarters · filed 2024-02-15 | $137.71M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-03-31 | $29.29M 10-Q · filed 2023-05-04 | $73.88M derived: sum of 2 quarters · filed 2024-02-15 | $107.24M derived: sum of 3 quarters · filed 2024-02-15 | $139.32M derived: sum of 4 quarters · filed 2024-02-15 |
| 2021-12-31 | $44.58M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $77.95M derived: sum of 2 quarters · filed 2024-02-15 | $110.03M derived: sum of 3 quarters · filed 2024-02-15 | $165.72M 10-K · filed 2024-02-15 |
| 2021-09-30 | $33.37M 10-Q · filed 2022-10-27 | $65.44M derived: sum of 2 quarters · filed 2022-10-27 | $121.14M 10-Q · filed 2022-10-27 | $155.41M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-06-30 | $32.08M 10-Q · filed 2022-07-28 | $87.77M 10-Q · filed 2022-07-28 | $122.04M derived: sum of 3 quarters · filed 2023-02-23 | $159.31M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-03-31 | $55.69M 10-Q · filed 2022-04-28 | $89.97M derived: sum of 2 quarters · filed 2023-02-23 | $127.23M derived: sum of 3 quarters · filed 2023-02-23 | $160.99M derived: sum of 4 quarters · filed 2023-02-23 |
| 2020-12-31 | $34.28M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $71.54M derived: sum of 2 quarters · filed 2023-02-23 | $105.30M derived: sum of 3 quarters · filed 2023-02-23 | $139.87M 10-K · filed 2023-02-23 |
| 2020-09-30 | $37.26M 10-Q · filed 2021-10-28 | $71.02M derived: sum of 2 quarters · filed 2021-10-28 | $105.60M 10-Q · filed 2021-10-28 | $171.79M derived: sum of 4 quarters · filed 2022-02-10 |
| 2020-06-30 | $33.76M 10-Q · filed 2021-08-03 | $68.33M 10-Q · filed 2021-08-03 | $134.53M derived: sum of 3 quarters · filed 2022-02-10 | $180.54M derived: sum of 4 quarters · filed 2022-02-10 |
| 2020-03-31 | $34.58M 10-Q · filed 2021-04-29 | $100.78M derived: sum of 2 quarters · filed 2022-02-10 | $146.78M derived: sum of 3 quarters · filed 2022-02-10 | $177.39M derived: sum of 4 quarters · filed 2022-02-10 |
| 2019-12-31 | $66.20M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-10 | $112.21M derived: sum of 2 quarters · filed 2022-02-10 | $142.81M derived: sum of 3 quarters · filed 2022-02-10 | $174.84M 10-K · filed 2022-02-10 |
| 2019-09-30 | $46.01M 10-Q · filed 2020-11-05 | $76.61M derived: sum of 2 quarters · filed 2020-11-05 | $108.64M 10-Q · filed 2020-11-05 | $136.62M derived: sum of 4 quarters · filed 2021-02-11 |
| 2019-06-30 | $30.60M 10-Q · filed 2020-08-06 | $62.63M 10-Q · filed 2020-08-06 | $90.61M derived: sum of 3 quarters · filed 2021-02-11 | $178.56M derived: sum of 4 quarters · filed 2021-02-11 |
| 2019-03-31 | $32.03M 10-Q · filed 2020-05-06 | $60.01M derived: sum of 2 quarters · filed 2021-02-11 | $147.96M derived: sum of 3 quarters · filed 2021-02-11 | $170.20M derived: sum of 4 quarters · filed 2021-02-11 |
| 2018-12-31 | $27.97M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-11 | $115.93M derived: sum of 2 quarters · filed 2021-02-11 | $138.17M derived: sum of 3 quarters · filed 2021-02-11 | $157.75M 10-K · filed 2021-02-11 |
| 2018-09-30 | $87.95M 10-Q · filed 2019-10-31 | $110.19M derived: sum of 2 quarters · filed 2019-10-31 | $129.78M 10-Q · filed 2019-10-31 | |
| 2018-06-30 | $22.24M 10-Q · filed 2019-08-06 | $41.83M 10-Q · filed 2019-08-06 | ||
| 2018-03-31 | $19.58M 10-Q · filed 2019-05-02 | |||
| 2017-12-31 | $92.82M 10-K · filed 2020-02-13 | |||
| 2012-12-31 | $12.70M 10-K · filed 2013-02-19 | |||
| 2011-12-31 | $17.10M 10-K · filed 2013-02-19 | |||
| 2010-12-31 | $19.40M 10-K · filed 2013-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |